Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.733400
Title: The development of gene therapy for recessive dystrophic epidermolysis bullosa
Author: Abdul Wahab, Alya Omar
ISNI:       0000 0004 6498 0685
Awarding Body: King's College London
Current Institution: King's College London (University of London)
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Thesis embargoed until 01 Oct 2023
Access from Institution:
Abstract:
Epidermolysis bullosa (EB) is a group of inherited mechanobullous disorders characterised by trauma induced blistering. One of the most severe subtypes is recessive dystrophic epidermolysis bullosa (RDEB). RDEB is due to loss of function mutations in the gene encoding type VII collagen (COL7A1), one of the main constituents of anchoring fibrils anchoring the basement membrane to the underlying dermis. There is no cure for this devastating condition although promising pre-clinical studies for strategies using genetic correction, protein replacement, cell therapy or drug therapies are underway. Reconstitution of COL7A1 expression in both keratinocyte and fibroblast cell populations has been demonstrated using ex vivo gene therapy and hypothesised to lead to new anchoring fibril formation and amelioration of disease phenotype. Feasibility of this approach had been demonstrated in pre-clinical studies using a retroviral vector, and this work details the development of a phase 1 clinical trial to graft an autologous gene corrected skin equivalent graft. Detailed analysis of a cohort of adult patients with RDEB was performed in order to identify suitable trial candidates. In addition, an alternative strategy using a lentiviral vector encoding codon-optimised COL7A1 developed in order to transduce fibroblasts to be administered intradermally was developed. Expression and secretion of full-length de novo C7 was confirmed, with transduced cells exhibiting increased levels of protein expression despite only modest transduction efficiencies. This work details the journey and obstacles encountered in developing gene therapy clinical trials for RDEB, both through the development of a phase 1 study for an autologous gene corrected skin equivalent graft as well as a phase I study of intradermal autologous gene corrected fibroblasts.
Supervisor: McGrath, John Alexander Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.733400  DOI: Not available
Share: